Table 1. Patient characteristics.
Table 1—source data 1. Comparative characteristics of the HC and PWH.
elife-82785-table1-data1.xlsx (11.3KB, xlsx)
Table 1—source data 2. Non-significant characteristics between the cohorts.
elife-82785-table1-data2.xlsx (13.7KB, xlsx)
| Complete Cohort | SNF-1 | SNF- 2 | SNF-3 | P values | |
|---|---|---|---|---|---|
| At-risk Classification | HC-like | Severe at risk | Mild | ||
| N | 97 | 19 | 44 | 34 | |
| Age in years, Median (IQR) | 54 (48–63) | 60 (48–68) | 54 (48–62) | 54 (51–60) | 0.75 |
| Gender, Male, N (%) | 84 (87) | 15 (79) | 40 (91) | 29 (85) | 0.36 |
| Ethnicity Caucasian, N (%) | 79 (81) | 15 (79) | 38 (87) | 26 (77) | 0.49 |
| Mode of transmission, N (%) Homosexual/bisexual Heterosexual Other/unknown |
63 (65) 26 (27) 8 (8) |
9 (47) 7 (37) 3 (16) |
36 (81) 6 (14) 2 (5) |
18 (53) 13 (38) 3 (9) |
0.017 |
| CD4 Nadir, cells/mL, Median (IQR) | 235 (123–320) | 240 (127–330) | 240 (145–365) | 223 (42–290) | 0.49 |
| CD4 at ART Initiation, cells/mL, Median (IQR) | 287 (155–410) | 270 (120–360) | 318 (192–463) | 240 (108–320) | 0.11 |
| Viral Load at ART initiation, log copies/mL, Median (IQR) | 5.02 (4.34–5.61) | 4.87 (4.32–5.5) | 5.11 (4.74–5.61) | 4.94 (4.2–5.55) | 0.35 |
| CD4 at sampling, cells/mL, Median(IQR) | 713 (570–900) | 680 (540–958) | 762 (689–923) | 610 (475–819) | 0.015 |
| CD8 at sampling, cells/mL, Median (IQR) | 775 (600–1100) | 780 (630–879) | 894 (638–1300) | 700 (530–870) | 0.054 |
| Viral load (<50 copies/mL), N (%) | 97 (100) | 19 (100) | 44 (100) | 34 (100) | 1 |
| Duration of treatment in years, median (IQR) | 15 (9–18) | 15 (13–18) | 15 (8–18) | 14 (7–17) | 0.73 |
| Current Treatment, 1st drug, N (%) ABC TDF/TAF Other |
31 (32) 42 (43) 24 (25) |
8 (42) 8 (42) 3 (16) |
13 (30) 19 (43) 12 (27) |
10 (29) 15 (44) 9 (27) |
0.84 |
| Current Treatment, 3rd drug, N (%) NNRTI PI/r INSTI Other |
38 (39) 18 (19) 15 (15) 26 (27) |
8 (42) 4 (21) 4 (21) 3 (16) |
14 (32) 11 (25) 6 (14) 13 (29) |
16 (47) 3 (9) 5 (15) 10 (29) |
0.45 |
| BMI, Mean (SD) | 24 (22–27) | 22 (19–25) | 26 (23–28) | 24 (22–27) | 0.003 |
| VAT, Median (IQR) | 89 (36–142) | 41 (19–106) | 127 (79–196) | 69 (26–100) | 0.0001 |
| SAT, Median (IQR) | 111 (70–167) | 69 (33–115) | 117 (82–174) | 119 (83–190) | 0.02 |
| MetS, N (%) | 43 (44) | 6 (32) | 31 (70) | 6 (17) | 0.000009 |
| Central obesity, N(%) | 57 (59) | 8 (42) | 32 (73) | 17 (50) | 0.033 |
| Waist circumference (cm) | 94 (87–101) | 90 (84–95) | 100 (91–105) | 90 (87–97) | 0.0007 |
| Hypertension, N (%) | 49 (51) | 5 (26) | 23 (52) | 21 (62) | 0.04 |